Tesamorelin therapy provides a significant reduction in visceral fat for patients with HIV-associated lipodystrophy, but it is not a cure. Studies suggest that the benefits of treatment may diminish after discontinuation of the therapy. Ongoing research aims to understand the long-term management of lipodystrophy, including the potential need for continuous or intermittent treatment with Tesamorelin.